Plain-English translation of NCT06442475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat slow-growing B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. is a type of immunotherapy that helps your immune system fight cancer cells. The study is looking at whether a lower dose of this medication can work effectively while potentially reducing side effects.
Most people with slow-growing lymphomas don't receive treatment right away because the disease often progresses slowly. This study is testing whether the medication could be an effective option for people newly diagnosed with these types of lymphomas, and whether a lower dose might make treatment safer and more tolerable.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the medication by infusion into your vein over 2–4 hours on four separate days (days 1, 8, 15, and 22). You'll have blood tests and imaging scans (PET/CT) done as part of the study to see how you're responding. After your treatment visits are complete, you'll return for follow-up appointments at week 13, 6 months, and then periodically for up to 5 years to make sure the treatment is working and to monitor your health.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States